文献速递肾小球疾病肾移植

基因分层激素抵抗型肾病综合征对首轮强化免疫抑制的应答

Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-04-21

该研究基于英国肾病综合征国家研究队列,对271例激素抵抗型肾病综合征患儿进行基因检测,分析首轮强化免疫抑制应答与疾病进展及移植后复发的关系。结果显示单基因病患者完全应答率仅4%,显著低于基因检测阴性患者的25%(P=0.02),且无移植后复发;基因阴性患者中完全应答者97%未进展,而无应答者44%发生肾衰竭且73%移植后复发。继发性激素抵抗完全应答率高于原发性(43% vs 23%,P=0.001),其中利妥昔单抗应答率最高(64%)。

要点

  • 单基因病激素抵抗型肾病综合征对强化免疫抑制应答差,但移植后无复发。
  • 基因检测阴性患者中,首轮强化免疫抑制完全应答者97%未进展。
  • 继发性激素抵抗完全应答率高于原发性,利妥昔单抗应答率最高(64%)。

核心结论

  • 单基因病激素抵抗型肾病综合征治疗应答差且移植后无复发。
  • 基因检测阴性患者首轮强化免疫抑制应答与长期结局相关。
  • 继发性激素抵抗更易应答,尤其对利妥昔单抗。

研究设计与样本

  • 基于英国肾病综合征国家研究队列的回顾性分析。
  • 纳入271例激素抵抗型肾病综合征患儿,其中178例接受强化免疫抑制且应答可评估。
  • 所有患者接受全基因组、全外显子或激素抵抗型肾病综合征基因 panel 测序。

主要发现

  • 单基因病患者完全应答率4%,基因检测阴性患者25%(P=0.02)。
  • 基因检测阴性完全应答者中97%未进展,无应答者44%发生肾衰竭。
  • 无应答者移植后复发率73%,单基因病患者无移植后复发。
  • 继发性激素抵抗完全应答率43%,原发性/推测抵抗23%(P=0.001)。
  • 继发性激素抵抗中对利妥昔单抗完全应答率最高(64%)。

关键数值与推荐

  • 完全或部分应答定义为开始强化免疫抑制后6个月内。
  • 单基因病完全应答率4% vs 基因阴性25%(P=0.02)。
  • 继发性激素抵抗完全应答率43% vs 原发性23%(P=0.001)。
  • 继发性激素抵抗对利妥昔单抗完全应答率64%。

临床怎么用

  • 对激素抵抗型肾病综合征患儿应进行基因检测以指导分层。
  • 基因检测阴性者若首轮强化免疫抑制无应答,需警惕进展至肾衰竭及移植后复发。
  • 继发性激素抵抗可优先考虑利妥昔单抗等强化免疫抑制方案。

局限性

  • 回顾性队列设计,应答评估依赖实验室数据。
  • 部分患者应答信息不可用,样本量有限。
  • 活检结果与应答及结局无相关性,未进一步阐明机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Intensified immunosuppression in steroid-resistant nephrotic syndrome is broadly applied, with disparate outcomes. This review of patients from the United Kingdom National Study of Nephrotic Syndrome cohort aimed to improve disease stratification by determining, in comprehensively genetically screened patients with steroid-resistant nephrotic syndrome, if there is an association between response to initial intensified immunosuppression and disease progression and/or post-transplant recurrence. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Pediatric patients with steroid-resistant nephrotic syndrome were recruited via the UK National Registry of Rare Kidney Diseases. All patients were whole-genome sequenced, whole-exome sequenced, or steroid-resistant nephrotic syndrome gene-panel sequenced. Complete response or partial response within 6 months of starting intensified immunosuppression was ascertained using laboratory data. Response to intensified immunosuppression and outcomes were analyzed according to genetic testing results, pattern of steroid resistance, and first biopsy findings. RESULTS: Of 271 patients, 178 (92 males, median onset age 4.7 years) received intensified immunosuppression with response available. A total of 4% of patients with monogenic disease showed complete response, compared with 25% of genetic-testing-negative patients (P=0.02). None of the former recurred post-transplantation. In genetic-testing-negative patients, 97% with complete response to first intensified immunosuppression did not progress, whereas 44% of nonresponders developed kidney failure with 73% recurrence post-transplant. Secondary steroid resistance had a higher complete response rate than primary/presumed resistance (43% versus 23%; P=0.001). The highest complete response rate in secondary steroid resistance was to rituximab (64%). Biopsy results showed no correlation with intensified immunosuppression response or outcome. CONCLUSIONS: Patients with monogenic steroid-resistant nephrotic syndrome had a poor therapeutic response and no post-transplant recurrence. In genetic-testing-negative patients, there was an association between response to first intensified immunosuppression and long-term outcome. Patients with complete response rarely progressed to kidney failure, whereas nonresponders had poor kidney survival and a high post-transplant recurrence rate. Patients with secondary steroid resistance were more likely to respond, particularly to rituximab.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Mason AE, Sen ES, Bierzynska A, et al. Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol. 2020. PMID: 32317330. doi:10.2215/CJN.13371019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。